Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONIZE: Sotatercept Extension Study in Cpc-PH with HFpEF
NCT06814145Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Aug 2035
- Modality
- Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of sotatercept in pulmonary hypertension (PH), sponsored by Merck & Co.. Started Apr 2025; status: active, not recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT06814145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814145.